Low-dosage micronized 17 beta-estradiol prevents bone loss in postmenopausal women.

Authors: Ettinger B, Genant HK, Steiger P, Madvig P.

Publication Year: 1992

Citation: Am J Obstet Gynecol 1992;166(2):479-88.

The authors evaluated the effects of 17 beta-estradiol (E2) in a randomized, double-blind, dose ranging study of 41 postmenopausal women conducted in 2 phases. Phase one included phased E2 doses (0.5mg, 1.0mg, 2.0mg) plus calcium supplementation (to serum value of 1500mg). Phase two included E2 doses plus random cessation of calcium supplementation. Progestins were added during phase two (total study time of 18 months). Results showed very little change in bone density results for placebo group (0.5 – 0.9%) whereas treatment group showed significant increases from baseline bone density. In phase two the treatment groups showed an annual change in bone density of 2.0%. There was a positive correlation between total calcium intake and the change in bone density results. The study showed a continuous dose-response effect on bone density results. Authors concluded that low dose (1.0mg) beta-estradiol and 1000mg of calcium prevented bone loss in postmenopausal women.